# US 8,540,964 B2 · Polyvalent conjugate vaccine for cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,540,964 B2 - Document ID: US8540964B2 - Status: Granted - Kind: B2 - Application number: 13/314,521 - Filed: 2011-12-08 - Published: 2012-10-18 - Granted: 2013-09-24 - Earliest claimed: 2001-07-06 - Assignees: Sloan-Kettering Institute for Cancer Research - Applicants: Philip O. Livingston; Govindaswami Ragupathi; Samuel J. Danishefsky - Inventors: Philip O. Livingston; Govindaswami Ragupathi; Samuel J. Danishefsky - Web page: https://patentgrep.com/patent/US8540964B2 ## CPC - A61K 39/385: Haptens or antigens, bound to carriers - A61P 35/00: Antineoplastic agents - A61K 39/001169: {Tumor associated carbohydrates} - A61K 39/00117: {Mucins, e.g. MUC-1} - A61K 39/001171: {Gangliosides, e.g. GM2, GD2 or GD3} - A61K 39/001172: {Sialyl-Thomson-nouvelle antigen [sTn]} - A61K 39/001173: {Globo-H} - A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines} - A61P 37/02: Immunomodulators - A61P 37/04: Immunostimulants - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS} - A61K 2039/575: {humoral response} - A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]} - A61K 2039/627: {characterised by the linker} - A61K 2039/70: {Multivalent vaccine} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject. ## Claims ### Claim 1 An immunogenic composition comprising an adjuvant and antigens comprising MUC-1, Tn, GloboH and TF(c), and said composition further comprising at least one antigen selected from the group consisting of sTn(c), Tn(c) and sialyl Lea, wherein said antigens are individually conjugated to a carrier. ### Claim 2 (depends on 1) The immunogenic composition of claim 1, wherein said antigens comprise MUC-1, Tn, GloboH, TF(c) and sTn(c). ### Claim 3 (depends on 1) The immunogenic composition of claim 1, wherein said antigens comprise MUC-1, Tn, GloboH, TF(c) and Tn(c). ### Claim 4 (depends on 1) The immunogenic composition of claim 1, wherein said antigens comprise MUC-1, Tn, GloboH, TF(c) and sialyl Lea. ### Claim 5 (depends on 1) The immunogenic composition of claim 1, wherein at least two antigens are selected from the group consisting of sTn(c), Tn(c) and sialyl Lea. ### Claim 6 (depends on 5) The immunogenic composition of claim 5, wherein said at least two antigens are sTn(c) and Tn(c). ### Claim 7 (depends on 5) The immunogenic composition of claim 5, wherein said at least two antigens are sTn(c) and sialyl Lea. ### Claim 8 (depends on 5) The immunogenic composition of claim 5, wherein said at least two antigens are Tn(c) and sialyl Lea. ### Claim 9 (depends on 1) The immunogenic composition of claim 1, wherein said antigens comprise MUC1, Tn, GloboH, TF(c), sTn(c), Tn(c) and sialyl Lea. ### Claim 10 (depends on 1) A method for inducing antibody production in a subject comprising administering an immunogenic composition of claim 1. ### Claim 11 An immunogenic composition comprising an adjuvant and antigens comprising MUC1-Tn conjugate, GloboH and TF(c), and said composition further comprising at least one antigen selected from the group consisting of sTn(c), Tn(c) and sialyl Lea, wherein said conjugate and each of said antigens are individually conjugated to a carrier. ### Claim 12 (depends on 11) The immunogenic composition of claim 11, wherein said antigens comprise MUC1-Tn conjugate, GloboH, TF(c) and sTn(c). ### Claim 13 (depends on 11) The immunogenic composition of claim 11, wherein said antigens comprise MUC1-Tn conjugate, GloboH, TF(c) and Tn(c). ### Claim 14 (depends on 11) The immunogenic composition of claim 11, wherein said antigens comprise MUC1-Tn conjugate, GloboH, TF(c) and sialyl Lea. ### Claim 15 (depends on 11) The immunogenic composition of claim 11, wherein at least two antigens are selected from the group consisting of sTn(c), Tn(c) and sialyl Lea. ### Claim 16 (depends on 15) The immunogenic composition of claim 15, wherein said at least two antigens are sTn(c) and Tn(c). ### Claim 17 (depends on 15) The immunogenic composition of claim 15, wherein said at least two antigens are sTn(c) and sialyl Lea. ### Claim 18 (depends on 15) The immunogenic composition of claim 15, wherein said at least two antigens are Tn(c) and sialyl Lea. ### Claim 19 (depends on 11) The immunogenic composition of claim 11, wherein said antigens comprise MUC1-Tn conjugate, GloboH, TF(c), sTn(c), Tn(c) and sialyl Lea. ### Claim 20 (depends on 11) A method for inducing antibody production in a subject comprising administering an immunogenic composition of claim 11. ### Claim 21 A method for inducing antibody production in a subject comprising administering an immunogenic composition comprising antigens comprising MUC1-Tn conjugate, GloboH and TF(c), wherein said conjugate and each of said antigens are individually conjugated to a carrier.